Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6333131 | 0.88 | SMN1; SMN2 (0.62) | SMN1; SMN2KDM4ERAB9AALDH1A1KMT2A | |
| SCHEMBL15380599 | 0.85 | SMN1; SMN2 (0.56) | SMN1; SMN2KDM4ERAB9AHPGDALDH1A1 | |
| SCHEMBL12584868 | 0.84 | SMN1; SMN2 (0.58) | SMN1; SMN2KDM4ERAB9AHPGDALDH1A1 | |
| SCHEMBL27850750 | 0.81 | SMN1; SMN2 (0.53) | SMN1; SMN2KDM4ERAB9AHPGDALDH1A1 | |
| SCHEMBL13236911 | 0.81 | SMN1; SMN2 (0.53) | SMN1; SMN2KDM4ERAB9AHPGDALDH1A1 | |
| SCHEMBL17514795 | 0.81 | SMN1; SMN2 (0.52) | SMN1; SMN2KDM4ERAB9AHPGDALDH1A1 | |
| SCHEMBL4909005 | 0.80 | SMN1; SMN2 (0.57) | SMN1; SMN2KDM4ERAB9AHPGDALDH1A1 | |
| SCHEMBL13216576 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2KDM4ERAB9AHPGDALDH1A1 | |
| SCHEMBL4902482 | 0.80 | MAOB (0.61) | SMN1; SMN2KDM4ERAB9APOLBTAAR1 | |
| SCHEMBL29950824 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2KDM4ERAB9AHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110665-A1 | Desleucyl glycopeptide antibiotics and methods of making same | KAHNE DANIEL (US) | 2004-06-10 | — | — | US | disclosed |
| US-6699836-B2 | Vancomycin analogs | THE TRUSTEES OF PRINCETON UNIVERSITY | 2004-03-02 | — | — | US | disclosed |
| EP-0667353-B1 | Glycopeptide antibiotic derivatives | LILLY CO ELI (US) | 2003-10-29 | — | — | EP | disclosed |
| EP-1016670-B1 | Glycopeptide antibiotic derivatives | LILLY CO ELI (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6518243-B1 | Desleucyl glycopeptide antibiotics and methods of making same | TRUSTEES OF PRINCETON UNIVERSITY | 2003-02-11 | — | — | US | disclosed |
| US-20020042365-A1 | Vancomycin analogs | TRUSTEES OF PRINCETON UNIVERSITY, THE | 2002-04-11 | — | — | US | disclosed |
| EP-1016670-A1 | Glycopeptide antibiotic derivatives | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| US-5977062-A | ACTIVE AGAINST ANTIBIOTIC RESISTANT BACTERIA | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110665-A1 | Desleucyl glycopeptide antibiotics and methods of making same | FUT6, FUT5, ST6GAL1 | SMN1; SMN2 3997/4885KDM4E 3838/4885RAB9A 1400/4885 |
| US-20020042365-A1 | Vancomycin analogs | VNN1, PTMS, ASNS | SMN1; SMN2 4173/4885KDM4E 2977/4885RAB9A 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.